These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 15954116

  • 1. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
    Samadi P, Grégoire L, Rassoulpour A, Guidetti P, Izzo E, Schwarcz R, Bédard PJ.
    Mov Disord; 2005 Jul; 20(7):792-802. PubMed ID: 15954116
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus.
    Moroni F, Cozzi A, Carpendo R, Cipriani G, Veneroni O, Izzo E.
    Neuropharmacology; 2005 May; 48(6):788-95. PubMed ID: 15829251
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM, Chase TN.
    Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys.
    Samadi P, Grégoire L, Bédard PJ.
    Neurobiol Dis; 2004 Jun; 16(1):246-53. PubMed ID: 15207281
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W.
    Brain Res Bull; 2006 Apr 14; 69(3):318-26. PubMed ID: 16564428
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain.
    Riahi G, Morissette M, Lévesque D, Rouillard C, Samadi P, Parent M, Di Paolo T.
    Neurochem Int; 2012 Dec 14; 61(7):1160-71. PubMed ID: 22940695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.